They concluded that serum level of albumin at admission is considered as a good indicator of the functional outcome and trials for the correction of hypoalbuminemia in acute ischemic stroke would be helpful to decrease the risk of poor outcome. The gene discussed is ALB; the disease is Hypoalbuminemia.